Digital Asset DirectTop Tech Gifts
News Media Group, Inc.
Contact Details Karl Wayne +1 334-440-6397 karl@newsmg.com Company Website https://newsmg.com/
November 14, 2022 11:30 AM Eastern Standard Time
Video
Digital Asset Direct
News ReleaseCORRECTING AND REPLACING: Ryan VanDePutte Joins Inspirant Group as Sales Director
Inspirant Group
Inspirant Group, the award-winning disruptive management Consulting firm, has appointed Ryan VanDePutte as Sales Director. With a multi disciplinary background, VanDePutte has deep experience in project delivery, enterprise, and mid-market sales, assisting companies in simplifying their unique business and technology challenges. In his new role, VanDePutte will drive transformation initiatives and business development for the fast-growing Chicagoland company. “We’re thrilled to welcome Ryan to our team of Unconsultants. It is the exact right time to have his leadership and expertise at this stage of Inspirant Group ’s growth as we continue to expand our service offerings,” said Meighan Newhouse, Co Founder and CEO, Inspirant Group. “I’m delighted to join Inspirant Group and the talented team of Unconsultants in developing the Appian practice area,” VanDePutte shared. “This will allow us to draw upon the team’s collective knowledge base and experience in delivering best in class transformation initiatives to our clients.” VanDePutte holds a Bachelor of Science degree in operations management and information systems from Ball State University - Miller School of Business. He resides in the Chicagoland area with his wife and three children. Founded in 2017, Inspirant Group is the award-winning, remote-first management “UNconsulting” firm that takes companies from inspiration to transformation. By stripping away the bureaucracy and complexity associated with the traditional “big 4” and mid-tier consulting firms, Inspirant ’s team of UNconsultants delivers high touch service and advises clients in three service lines: strategy & operational agility, talent & organization, and technology & data. This mirrors the company’s approach to any engagement: optimize processes, ensure the right people are in the right seats, and make the tech and data work for the client (and not the other way around). Headquartered in Chicago, Illinois, Inspirant is Certified™ by Great Place to Work ®, the employee experience award, and was honored with two 2022 Built In awards including Best Remote-First Places to Work in the US and 22 StartUps to Watch in Chicago. For more information, visit: Inspirantgrp.com and follow us on LinkedIn. Contact Details Julie Livingston +1 347-239-0249 julie@wantleverage.com Company Website https://inspirantgrp.com
November 14, 2022 09:30 AM Central Standard Time
News ReleaseCan This Company’s Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval?
Organicell Regenerative Medicine, Inc.
Learn More about Organicell Regenerative Medicine, Inc. by gaining access to the latest research report In the medical community, the popularity of regenerative medicine is reportedly soaring primarily because research around these therapies shows promise in treating a wide range of musculoskeletal pain conditions. Armed with the belief that the human body can heal itself, regenerative medicine treatments like exosome therapy and stem cell therapy are advancing. But regenerative medicine has sometimes been embroiled in controversy beginning in 1981 when scientists discovered ways to derive embryonic stem cells from early mouse embryos. That discovery was followed by a method to derive stem cells from human embryos and grow the cells in the laboratory in 1998. Massive players like Amgen Inc. (NASDAQ: AMGN), Sanofi SA (NASDAQ: SNY), and Gilead Sciences Inc. (NASDAQ: GILD) have advanced stem cell research and therapies. Is Exosome Therapy Different? Unlike stem cell therapy, Organicell’s (OTCMKTS: OCEL) exosome therapy doesn't involve using donor cells or umbilical cords. Instead, the exosomes are extracted from full term, planned C Section, Amniotic fluid. The extracted exosome solution is derived from amniotic fluid and contains over 300 soluble proteins as growth factors, cytokines and chemokines, extracellular matrix proteins as fibronectin and collagen, structural molecules as hyaluronic acid, Nanoparticles as extracellular vesicles, exosomes and surfactants proteins, valuable lipids, micro-RNA, messenger-RNA, and cytokines. Exosome therapy, according to experts, is a highly targeted, flexible treatment believed to help inflammatory conditions like COPD, Long Covid, musculoskeletal injuries, osteoarthritis, and chronic pain. What’s the difference between Exosomes and Stem Cells? Try to think of Stem Cells as microchips in a computer. Exosomes are like the software. South Florida-based Organicell Regenerative Medicine Inc. (OTCMKTS: OCEL) is a company that is a pioneer in the exosome space. Their products are designed to operate like software for the computers of our body known as cells. However, the software Organicell uses is naturally occurring and unaltered. Organicell extracts its exosomes from what is believed to be one of the most naturally healing fluids on the planet, amniotic fluid. The software/exosomes in this fluid reminds the body what it used to do when it was young. To put things plainly, the “software” (exosomes) is a set of instructions, data or programs used to operate the “computers” (cells) and execute specific tasks, while a computer-chip (stem cells) are used more as building blocks in regenerative medicine. Potential Benefits The potential benefits of Organicell’s products could be enormous. For example, the company's investigational product Zofin™ is an acellular, non-HCT/P biologic, currently being studied in clinical trials. The company accomplished the difficult task of an approved investigational new drug (IND) from the U.S. Food and Drug Administration (FDA) which lead to approved clinical trials.. Zofin™ is derived from perinatal sources and is manufactured to retain the naturally occurring nanoparticles and microRNAs without manipulation or adding or combining any other substance. Zofin™ is currently being studied in FDA Phase I/II clinical trials for COVID-19, Long Covid, Chronic Obstructive Pulmonary Disease (COPD), and ready to begin a trial for Osteoarthritis of the knee. Below are the results that were published on the COVID patients treated with Zofin under eIND approval. The important items in the chart are the key biomarkers that measure inflammation: IL-6 and CRP as well as the chest X Rays that show the structural difference in the lungs over time. A Better Approach? Organicell reports that its mission is to be the first company to prove the efficacy of extracellular vesicles (EV's) — a.k.a exosomes — on inflammatory ailments. Organicell has two active FDA approved clinical trials for Long Covid and COPD. The company says through its ground-breaking research in the field of nanotechnology, specifically perinatal-derived EVs, it has created the drug candidate, Zofin, that could be the next frontier of regenerative biologic therapeutics. Organicell’s proprietary product’s biological representation is allogenic amniotic fluid (secreted body fluid, non-HCT/Ps), which is an acellular product derived from human amniotic fluid (HAF). The product contains no addition or combination of any other substance or diluent during production. Moreover, the product quality assurance is seemingly unmatched in the regenerative medicine space. the donor from whom this product was derived has been tested and found negative for the following: HBsAg (Hepatitis B Surface Antigen), HBcAb (hepatitis B core antibody), HCV (hepatitis C antibody), HIV I/II-Ab (Antibody to Human Immunodeficiency Virus Types 1 and 2), Syphilis detection test, HIV NAT (HIV Nucleic Acid Test), and HCV NAT (HCV Nucleic Acid Test). Additional donor screening tests may have been performed on the donor. If additional tests for Human Immunodeficiency Virus, Hepatitis B, Hepatitis C or Syphilis were performed, the results were reviewed and found to be NEGATIVE. Additional tests for other communicable diseases, such as West Nile Virus, T. Cruzi, Cytomegalovirus and Epstein Barr Virus may have been performed. The results of all additional communicable disease tests have been evaluated by the Medical Director and have been found acceptable according to regulations, standards and Standard Operating Procedures (SOPs). Donor screening tests are performed by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and American Association of Blood Banks (AABB) using FDA licensed tests when available performed by VRL Laboratories. The donor is selected based on medical and social history which meets the Standards of the American Association of Tissue Banks (AATB) United States Public Health Service (USPHS), and the Federal Food and Drug Administration (FDA). Donor suitability was determined by the Manufacturing Facilities’ Medical Directors (Organicell Regenerative Medicine, 1951 NW 7th Ave, Suite 300, Miami, FL 33136). Organicell Factor X is manufactured for clinical use under cGMP-compliant manufacturing facility, to control potency and purity of the product. Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will", "believes", "expects", "potential", or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Organicell Investor Relations IR@organicell.com Company Website https://organicell.com/
November 14, 2022 09:17 AM Eastern Standard Time
Image
News ReleaseInsurance Services LLC Joins AmeriLife to Expand Opportunities for Agents & Serve More Medicare Beneficiaries
AmeriLife
AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions, announced today that it has partnered with Insurance Services LLC, a national distributor of Medicare Advantage and Medicare Supplement solutions. Headquartered in Greensburg, Penn., Insurance Services expands AmeriLife’s presence across the state and opens up new opportunities for agents with a number of top regional and national carriers. Per the agreement, terms of the deal were not disclosed. "I’ve long admired and respected AmeriLife for how they run their business and the positive impact that they’ve had on our industry,” said Larry Mikolajcik, CEO of Insurance Services. “Our team is excited for this new partnership. It will bring the technology and resources necessary to take our business to the next level, stay ahead of the changing pace of business, and deliver on our promise to our agents and their clients right here, at home, and across the country." Founded 42 years ago out of a small hotel room in western Pennsylvania, Insurance Services now boasts 10 offices and more than 100,000 clients across the commonwealth as well as in Ohio, West Virginia, Maryland and Florida. The firm has become a household name thanks in part to its popular spokesperson – professional football Hall of Famer and legendary Steelers linebacker Jack Ham – and its team of more than 300 licensed agents renowned for their command of the Medicare space and access to some of the top regional and national contracts in the business. “We couldn’t be more excited to welcome Larry and the Insurance Services team to AmeriLife,” said Mike Vietri, AmeriLife’s Chief Distribution Officer. “Larry is a legend in our industry, and he and his team stand as testament to building a business the right way: by developing agents that are dedicated to the firm’s values and committed to delivering – as their motto says – ‘satisfaction through service’. I firmly believe we will be stronger together, and we look forward to supporting Insurance Services’ continued growth.” ### About Insurance Services LLC Founded in 1980, Insurance Services LLC is a family-owned and operated insurance marketing organization that primarily distributes Medicare Advantage and Medicare Supplement products. The firm, which is headquartered in Greensburg, Penn., has more than 300 licensed agents that deliver “satisfaction through service” to Medicare-eligible beneficiaries nationwide. For more information, visit MyInsuranceTeam.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/
November 14, 2022 09:00 AM Eastern Standard Time
Digital Asset DirecthVIVO hails growing contract values after winning £13.6mln RSV challenge trial deal
hVIVO PLC
Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
November 14, 2022 06:14 AM Eastern Standard Time
Video
News ReleaseElsevier Secures Publishing Rights for Premium Titles for 2023
Elsevier
Elsevier, a leading scientific publisher, and global information analytics business specializing in science and health, announced today that it will be the new publisher of six influential society journals starting in January 2023: American Journal of Clinical Nutrition The Journal of Nutrition Journal of Thrombosis and Haemostasis American Journal of Transplantation Laboratory Investigation Modern Pathology The newly acquired titles represent the following societies and add to Elsevier’s expansive global health publishing portfolio: American Society for Nutrition ( ASN ) United States and Canadian Academy of Pathology ( USCAP ) International Society on Thrombosis and Haemostasis ( ISTH ) The American Society of Transplant Surgeons ( ASTS ) American Society of Transplantation ( AST ) All are considered internationally renowned sources of knowledge and impactful study in the fields of pathology, nutrition, transplantation, haematology and peripheral vascular disease. “ It is an honor to partner with five established societies that have trusted Elsevier as the official publisher of their important journals. True to our commitment to supporting research and clinical practice, we are dedicated to placing our full range of industry-leading resources for authors, editors, reviewers and readers, in the disposal of our latest additions. With our continuous support and seamless collaboration these six valued titles can harness the benefits of a reliable global publishing partner allowing them to maximize their contribution to scientific research and clinical practice in their respective fields” said Carl Schwarz Senior Vice President, Health and Medical Sciences, at Elsevier. Elsevier will officially welcome the journals into their portfolio beginning in January 2023. They will be part of Elsevier’s title-by-title subscription model instead of a collection. Learn more about these exceptional titles or contact us for more information. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions, and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our over 2,700 digitized journals, including The Lancet and Cell; our over 43,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details Elsevier Dan DiPietro-James, Global Media Relations Director +1 773-251-8744 dan.james@elsevier.com Company Website https://www.elsevier.com/
November 14, 2022 03:00 AM Eastern Standard Time
News ReleaseFine Hygienic Holding Wins License to Market FIFA World Cup Qatar 2022™ Facial Tissues and Will Be Providing Hygiene Support During the Tournament
Fine Hygienic Holding
Football's world governing body FIFA has awarded Fine Hygienic Holding (FHH) the license to design, produce, and sell limited-edition packs of facial tissues commemorating the FIFA World Cup Qatar 2022™. FHH launched the special edition packs in hypermarkets and supermarkets in Jordan, Egypt, Saudi Arabia, the UAE, Bahrain, Oman, Kuwait, Iraq, Morocco, and Sudan in mid-September 2022. FHH will also be providing sanitation support at the tournament itself, working across the 8 stadiums, training sites, and FIFA Fan Festivals to ensure the highest level of hygiene for fans, teams, and players attending FIFA World Cup Qatar 2022™. Commenting on this occasion, James Michael Lafferty, FHH CEO, said, "“We at Fine are delighted to be supporting the hygiene program at the FIFA World Cup, and ensuring we help make this the most hygienically protected sports event since the pandemic. Our Fine Guard products, with long lasting germ protection, are a perfect solution for areas such as stadiums where constant foot traffic renders only brief disinfection with traditional products. Spectators and everyone involved can rest easy knowing FIFA is using state of the art products and technologies." The FIFA World Cup Qatar 2022™ will be the first World Cup ever to be held in the Arab World. It is scheduled to take place from November 20 to December 18, 2022, in Qatar, with matches being played across eight stadiums, hosting 32 teams. About Fine Hygienic Holding: Fine Hygienic Holding (FHH), one of the world's leading wellness groups and MENA's leading manufacturer of hygienic products, serves consumers in more than 80 countries around the world. Originally established as a paper manufacturer, FHH has transformed into a wellness company dedicated to enhancing global health and wellbeing. FHH offers a diverse array of award-winning products including sterilized facial tissues, napkins, kitchen towels, toilet paper, baby diapers, adult briefs, jumbo rolls, as well as away-from-home products to accommodate all types of private and public institutions, in addition to its advanced range of personal protective equipment (PPE) and long-lasting germ protection solutions, it also brings innovative nutritional supplements, Motiva, to the market. Contact Details FINE HYGIENIC HOLDING Rana Kawalit | │ Corporate Communication & PR Director +971 54 531 5575 Rkawalit@finehh.com Company Website https://www.finehh.com/
November 14, 2022 12:30 AM Eastern Standard Time
News ReleaseThe Blood Supply Shortage: Why it’s Happening and How You Can Help
YourUpdateTV
A video accompanying this announcement is available at: https://youtu.be/8kShJVgN2pc This is the worst blood shortage in over a decade, posing a concerning risk to patient care. Amid this crisis, doctors have been forced to make difficult decisions about who receives blood transfusions and who will need to wait until more products become available. Blood and platelet donations are critically needed to help prevent further delays in vital medical treatments. The blood supply took a major hit about as the Covid-19 pandemic took over the healthcare system. Shortages could potentially lead to the postponement of surgeries, other medical procedures, and be a major issue if a mass casualty event were to happen. Every year 4.5 million Americans will need a blood transfusion. Someone in your audience or their loved one could be in need. With the blood shortage being a major health issue potentially affecting so many, what can be done and what should we know? Dr. Glenn Ramsey, chair of the College of American Pathologists Transfusion Committee recently conducted a nationwide media tour to inform the public on what is being done. Topics that Dr. Ramsey discussed included: With the current blood shortage, the recent changes in blood donation restrictions The importance of donating blood Keeping the blood supply strong Why there is always a shortage How the current blood supply is being maximized What the most common incidents are in which blood donation is needed For more information please visit americasblood.org and newsroom.cap.org Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com
November 11, 2022 11:00 AM Eastern Standard Time
Video
News ReleaseFall Health Checklist from the College of American Pathologists
YourUpdateTV
A video accompanying this announcement is available at: https://youtu.be/DotHvhg8XQw Summer is coming to a close, which means it’s the perfect time to take stock of your health and set yourself up for success the rest of the year. The FDA has recently changed their guidelines regarding Covid at-home tests, now advising people to take three tests, instead of the previously recommended two tests. The agency issued the update just ahead of the back-to-school season – an attempt to reduce the risk of infection being missed and to help people from unknowingly spreading the virus. But COVID isn’t the only thing on people’s minds. With fall approaching, cold and flu season isn’t far behind. This time of year can create confusion for people who may not be able to tell the difference between COVID symptoms and cold/flu symptoms. There are also concerns about the spread of Monkeypox and the re-emergence of Polio. During a nationwide media tour on September 15 th, Dr. Emily Volk – President of the College of American Pathologists discussed: Changing FDA guidelines around COVID testing and what you need to know Navigating flu shots and COVID boosters Tips for knowing the difference between COVID symptoms and cold/flu symptoms Additional insights on recent health concerns such as Monkeypox and Polio For more information, visit CDC.GOV or FDA.GOV Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com
November 11, 2022 10:31 AM Eastern Standard Time
Video